NICE has published Technology Appraisal (TA) 445 on Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs.
Certolizumab pegol alone, or in combination with methotrexate, is recommended as an option for treating psoriatic arthritis only if:
- it is used as described in NICE technology appraisal guidance on Etanercept, infliximab and adalimumab for the treatment of psioratic arthritis (TA199, recommendations 1.1 and 1.2) or
- the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has stopped responding after the first 12 weeks.
Secukinumab alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if:
- it is used as described in NICE TA199 (recommendations 1.1 and 1.2) or
- the person has had a TNF-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or
- TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in TA199).
Certolizumab pegol and secukinumab are only recommended if the company provides them as agreed in their respective patient access schemes. Please review the complete technology appraisal for the full description of recommendations.
The planned appraisal on Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy, TA444, was terminated because no evidence was submitted by the responsible company.